British & American Net Asset Value(s)
28 September 2018 - 12:31AM
UK Regulatory
TIDMBAF
Net Asset Value
This announcement is made further to the publication earlier today of our
Half-year Report to 30th June 2018.
In our Report, Net Asset value as at 25th September 2018 was shown as GBP26.1
million, equivalent to 65 pence per share (prior charges deducted at par) and
75 pence per share on a fully diluted basis. This was based on the closing
market price on 24th September for our largest investment, Geron Corporation,
of $6.38 per share.
Since the publication of our Report earlier today, Geron Corporation has
unexpectedly announced the discontinuation of its collaboration agreement with
Janssen Biotech Inc (a unit of Johnson & Johnson) for the development of
Geron's oncology drug, Imetelstat, currently in clinical trials for two
hematologic (blood) cancer indications, Myelofibrosis (MF) and Myelodysplastic
Syndrome (MDS) . Janssen's decision follows a strategic review and
prioritisation of assets within its portfolio. Geron now regains full
ownership of all rights and clinical trial data to Imetelstat previously
assigned to Janssen.
As noted in our Report, the share price of Geron has increased substantially in
recent months in reaction to positive developments in its clinical trials and
in anticipation of a positive decision by Janssen to continue its collaboration
with Geron, which had been accelerated to the end of the third quarter. As a
result of today's decision by Janssen not to continue the collaboration with
Geron, the Geron share price is likely to fall substantially and this is likely
to have a material impact on our previously announced net asset value.
END
(END) Dow Jones Newswires
September 27, 2018 10:31 ET (14:31 GMT)
British & American Inves... (LSE:BAF)
Historical Stock Chart
From Apr 2024 to May 2024
British & American Inves... (LSE:BAF)
Historical Stock Chart
From May 2023 to May 2024